Anti-mechanical allodynic effect of intrathecal and intracerebroventricular injection of orexin-A in the rat neuropathic pain model

Yamamoto, Tatsuo; Saito, Osamu; Shono, Koyo; Aoe, Tomohiko; Chiba, Tetsuhiro

doi:10.1016/s0304-3940(03)00716-x

Cited by 62 publications

(38 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OX-B may elicit its effect by facilitating glycine release presynaptically. Behavioral studies support these electrophysiological findings, because intrathecal administration of OX-A and, to a lesser extent, OX-B inhibits withdrawal responses and spontaneous nociceptive behaviors in acute, chemical, inflammatory, neuropathic, and postsurgical pain models (Yamamoto et al, , 2003aCheng et al, 2003;Kajiyama et al, 2005;Mobarakeh et al, 2005a;Jeong and Holden, 2009). The antinociceptive effects of the orexins are blocked by intrathecally administered SB-334867, once again suggesting that pain modulation may be mediated through OX 1 receptors.…”

Section: B Orexin Influences On Peripheral Physiologymentioning

confidence: 71%

“…The antinociceptive effect is blocked by administration of SB-334867, suggesting the effects may be mediated by OX 1 receptors. In fact, OX-B is less potent than OX-A in attenuating the pain response in these models (Bingham et al, 2001;Yamamoto et al, 2003a;Mobarakeh et al, 2005b). OX-A may modulate supraspinal histamine release, because the effects of OX-A in acute and chemical pain models are enhanced in H 1 or H 2 receptor knockout mice or with the administration of H 1 or H 2 antagonists (Mobarakeh et al, 2005a).…”

Section: B Orexin Influences On Peripheral Physiologymentioning

confidence: 99%

See 1 more Smart Citation

International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology

et al. 2012

View full text Add to dashboard Cite

Section: B Orexin Influences On Peripheral Physiologymentioning

confidence: 71%

Section: B Orexin Influences On Peripheral Physiologymentioning

confidence: 99%

International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology

et al. 2012

View full text Add to dashboard Cite

“…Peripherally, orexin fibers and receptors have been localized to the pituitary, adrenal glands, gut, and testis (Blanco et al, 2001;Johren et al, 2001). The broad projections of the orexinergic system have led to its implication in a variety of functions, including feeding, sleep wake cycle, cardiovascular function, hormone secretion (Ferguson and Samson, 2003;Siegel, 2004;Sakurai, 2005;Samson et al, 2005) and more recently the modulation of nociceptive processing (Bingham et al, 2001;Cheng et al, 2003;Yamamoto et al, 2003;Kajiyama et al, 2005).…”

mentioning

confidence: 99%

Orexin 1 Receptor Activation Attenuates Neurogenic Dural Vasodilation in an Animal Model of Trigeminovascular Nociception

Holland¹,

Akerman²,

Goadsby³

2005

J Pharmacol Exp Ther

120

View full text Add to dashboard Cite

The pathophysiology underlying the pulsating quality of the pain of a migraine attack is not fully understood, although trigeminal vascular afferents containing the sensory neuropeptide calcitonin gene-related peptide (CGRP) must have a role. Antimigraine drugs, such as triptans, serotonin 5-hydroxytryptamine 1B/1D receptor agonists, reproducibly block neurogenic vasodilation associated with CGRP release. We examined the effects of the hypothalamic neuropeptides orexin A and orexin B on neurogenic dural vasodilation, dissecting out the receptor pharmacology with the novel orexin 1 (OX 1 ) receptor antagonist N-(2-methyl-6-benzoxazolyl)-NЉ-1,5-naphthyridin-4-yl urea (SB-334867). Electrical stimulation of dural afferents (50 -300 A) resulted in reproducible dural vasodilation of 136 Ϯ 9%. Orexin A 30 g kg Ϫ1 , but not 3 and 10 g kg Ϫ1 ,inhibited the dilation brought about by electrical stimulation over 60 min and maximally after 15 min by 60% (t 7 ϭ 7.138; P Ͻ 0.001; n ϭ 8). This response was reversed by pretreatment with the OX 1 receptor antagonist SB-334867. Addition of CGRP at the point of maximal effect of orexin A produced a further significant decrease in neurogenic dural vasodilation compared with orexin A only. CGRP administration (1 g kg Ϫ1 ) produced a reproducible dural blood vessel dilation of 145 Ϯ 7% that was not inhibited by intravenous administration of orexin A (30 g kg Ϫ1 ). Orexin B had no significant effect even at the highest dose. The current study demonstrates that orexin A is able to inhibit neurogenic dural vasodilation via activation of the OX 1 receptor, resulting in inhibition of prejunctional release of CGRP from trigeminal neurons.

show abstract

“…Orexins are implicated in a variety of functions, including feeding, sleep-wake cycle, cardiovascular function, hormone secretion, and, as discovered recently, the modulation of nociceptive processing [61][62][63][64]. The orexins also are of importance in weight control.…”

Section: Obesity Influencing the Central Events In Migrainementioning

confidence: 99%

Obesity and Chronic Daily Headache

Bigal

Rapoport

2011

Curr Pain Headache Rep

View full text Add to dashboard Cite

Obesity may be the greatest epidemic of modern times. It leads to diabetes and heart disease and shortens lifespan. Although not a risk factor for migraine, it is associated with an increased frequency and intensity of migraine. Obesity is also comorbid with chronic daily headache and is a major risk factor for chronification of episodic migraine in adults and children. Although obesity is not a factor in the effectiveness of migraine treatment, it does increase the peripheral and central events in migraine, ultimately increasing the neurologic potential for migraine. Although evidence suggests that obesity is a modifiable risk factor for migraine progression, it is unknown if weight loss is related to decrease in headache frequency. Recent surgical results suggest that this is true. We suggest all possible effective techniques aimed at weight loss be undertaken for migraineurs, especially obese migraineurs, and that carefully monitoring weight changes should be routinely done as part of their migraine care.

show abstract

Anti-mechanical allodynic effect of intrathecal and intracerebroventricular injection of orexin-A in the rat neuropathic pain model

Cited by 62 publications

References 9 publications

International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology

International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology

Orexin 1 Receptor Activation Attenuates Neurogenic Dural Vasodilation in an Animal Model of Trigeminovascular Nociception

Obesity and Chronic Daily Headache

Contact Info

Product

Resources

About